Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04091373
Recruitment Status : Not yet recruiting
First Posted : September 16, 2019
Last Update Posted : September 16, 2019
Sponsor:
Information provided by (Responsible Party):
MedImmune LLC

Brief Summary:
This is a randomized, open label, cross-over study in healthy adult subjects to investigate cotadutide exposure after subcutaneous injection at 3 different anatomical sites. The study will be conducted at a single US center. Each subject will be randomized to receive a single SC dose of 100 μg cotadutide via a pen device according to 6 sequences of dosing. Each SC injection will be administered by a health care provider at a different injection site (arm, thigh, or abdomen) in each period. SC injection in the abdomen will be used as the reference treatment to determine the relative PK of cotadutide 100 μg SC injections in the arm and thigh. Each SC injection of cotadutide will be separated by 7 days washout. Blood samples for PK analyses of cotadutide will be taken pre dose and at 11 time points up to 48 hours after dosing (Days 3, 10, and 17).

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Mellitus Combination Product: cotadutide multidose pen injection Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Phase 1, Randomized, Open-label, Single Center, Three Period Cross-over Study to Evaluate the Pharmacokinetics of Single Dose Administration of Cotadutide in Healthy Subjects
Estimated Study Start Date : September 17, 2019
Estimated Primary Completion Date : April 24, 2020
Estimated Study Completion Date : April 24, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Sequence 1
100ug SC injection cotadutide in the upper arm on Day 1, in the lower abdomen on Day 8, and in the thigh on Day 15
Combination Product: cotadutide multidose pen injection
SC injection in the upper arm

Combination Product: cotadutide multidose pen injection
SC injection in the lower abdomen

Combination Product: cotadutide multidose pen injection
SC injection in the thigh

Experimental: Sequence 2
100ug SC injection cotadutide in the thigh on Day 1, in the upper arm on Day 8, and in the lower abdomen on Day 15
Combination Product: cotadutide multidose pen injection
SC injection in the upper arm

Combination Product: cotadutide multidose pen injection
SC injection in the lower abdomen

Combination Product: cotadutide multidose pen injection
SC injection in the thigh

Experimental: Sequence 3
100ug SC injection cotadutide in the lower abdomen on Day 1, in the thigh on Day 8, and in the upper arm on Day 15
Combination Product: cotadutide multidose pen injection
SC injection in the upper arm

Combination Product: cotadutide multidose pen injection
SC injection in the lower abdomen

Combination Product: cotadutide multidose pen injection
SC injection in the thigh

Experimental: Sequence 4
100ug SC injection cotadutide in the thigh on Day 1, in the lower abdomen on Day 8, and in the upper arm on Day 15
Combination Product: cotadutide multidose pen injection
SC injection in the upper arm

Combination Product: cotadutide multidose pen injection
SC injection in the lower abdomen

Combination Product: cotadutide multidose pen injection
SC injection in the thigh

Experimental: Sequence 5
100ug SC injection cotadutide in the lower abdomen on Day 1, in the upper arm on Day 8, and in the thigh on Day 15
Combination Product: cotadutide multidose pen injection
SC injection in the upper arm

Combination Product: cotadutide multidose pen injection
SC injection in the lower abdomen

Combination Product: cotadutide multidose pen injection
SC injection in the thigh

Experimental: Sequence 6
100ug SC injection cotadutide in the upper arm on Day 1, in the thigh on Day 8, and in the lower abdomen on Day 15
Combination Product: cotadutide multidose pen injection
SC injection in the upper arm

Combination Product: cotadutide multidose pen injection
SC injection in the lower abdomen

Combination Product: cotadutide multidose pen injection
SC injection in the thigh




Primary Outcome Measures :
  1. Area under the plasma concentration time curve [ Time Frame: 48 hours ]
    To evaluate exposure following a single subcutaneous dose of cotadutide at each of 3 different sites of injection.


Secondary Outcome Measures :
  1. Maximum observed plasma drug concentration [ Time Frame: 48 hours ]
    To evaluate exposure following a single subcutaneous dose of cotadutide at each of 3 different sites of injection.

  2. Area under the plasma concentration time curve from zero to infinity [ Time Frame: 48 hours ]
    To evaluate exposure following a single subcutaneous dose of cotadutide at each of 3 different sites of injection

  3. Time to maximum observed plasma drug concentration [ Time Frame: 48 hours ]
    To evaluate exposure following a single subcutaneous dose of cotadutide at each of 3 different sites of injection

  4. Terminal phase elimination half life [ Time Frame: 48 hours ]
    To evaluate exposure following a single subcutaneous dose of cotadutide at each of 3 different sites of injection

  5. Apparent clearance [ Time Frame: 48 hours ]
    To evaluate exposure following a single subcutaneous dose of cotadutide at each of 3 different sites of injection.

  6. Anti drug antibody incidence and titer [ Time Frame: 43 Days ]
    To evaluate the immunogenicity of a single subcutaneous dose of cotadutide at each of 3 different sites of injection

  7. Incidence of treatment-emergent adverse events, including those related to changes in vital signs (including body temperature, heart rate and blood pressure) and safety laboratory evaluations (including hematology, serum chemistry, and plasma glucose). [ Time Frame: 43 Days ]
    To evaluate the safety and tolerability of a single subcutaneous dose of cotadutide at each of 3 different sites of injection.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy subjects aged 18 through 60 years (inclusive) at the time of screening.
  2. Electronic and/or written informed consent obtained from the subject prior to performing any protocol-related procedures, including screening evaluations.
  3. BMI between 19 and 30 kg/m2 (inclusive) at screening.
  4. Good general health as judged by the investigator, based on medical history, physical examination including 12 lead electrocardiogram (ECG), vital signs, and blood and urinary laboratory assessments.
  5. Female subjects of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the start of investigational product, and must not be breastfeeding.
  6. Female subjects of childbearing potential who are sexually active with a male partner must be using at least one highly effective method of contraception from screening and up to 4 weeks after the last dose of investigational product. As applicable, at least one method must be in effect prior to receiving the first dose of investigational product.

Exclusion Criteria:

  1. History of, or any existing condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product, put the subject at risk, influence the subject's ability to participate, or affect interpretation of subject safety or study results.
  2. Inflammatory bowel disease, gastroparesis or other severe disease or surgery affecting the upper GI tract, which may affect gastric emptying or could affect the interpretation of safety and tolerability data.
  3. Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2; eGFR will be determined by the chronic kidney disease - epidemiology collaboration (CKD-EPI) equation.
  4. BP and heart rate in supine position outside the ranges of 90 140 mmHg systolic, 50-90 mmHg diastolic and heart rate 40-100 beats/min following a 10 minute rest period.
  5. Active hepatitis B, measured by positive tests of surface antigen HBsAg and/or active hepatitis C, measured by positive hepatitis C virus antibody tests.
  6. Positive human immunodeficiency virus (HIV) antibodies.
  7. Subjects with a history of acute or chronic pancreatitis.
  8. Subjects with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and subjects with a screening/baseline serum calcitonin ≥ 50 ng/L.
  9. Signs or symptoms of severe hepatic impairment AND any of the following laboratory values at screening: Aspartate transaminase (AST) ≥ 3 × upper limit of normal (ULN), alanine transaminase (ALT) ≥ 3 × ULN, or total bilirubin (TBL) ≥ 2 × ULN. Alternatively, AST ≥ 5 × ULN, ALT ≥ 5 × ULN, or TBL ≥ 2 × ULN regardless of signs and symptoms. An isolated increase in TBL in subjects with known Gilbert's syndrome is not a reason for exclusion.
  10. Symptoms of acutely decompensated blood glucose control (eg, thirst, polyuria, weight loss), a history of type 1 diabetes mellitus or diabetic ketoacidosis.
  11. History of neoplastic disease within 5 years prior to screening except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer.
  12. Known or suspected allergy to cotadutide, any component of the formulation, or related products.
  13. Use of any prescription or nonprescription medication, with the exception of permitted concomitant medications, within the last 72 hours prior to Day 1.
  14. History of alcoholism or drug abuse during the last 12 months.
  15. Current smoker of cigarettes or other tobacco products.
  16. Habitual excessive consumption of methylxanthine containing (theophylline, caffeine, or theobromine) beverages and foods (eg, coffee, tea, red bull, cola, chocolate) as judged by the investigator.
  17. Blood donation within the last 3 months.
  18. Participation in any other study investigating other products or involving blood sampling within the past 30 days.
  19. Potentially noncompliant or uncooperative, as judged by the investigator.
  20. Substance dependence likely to impact subject safety or compliance with study procedures, to include a positive test result for drugs of abuse and/or alcohol at screening or prior to administration of investigational product on Day 1.
  21. Psychiatric illness such that subjects have been committed to an institution by way of official or judicial order.
  22. Involvement of any AstraZeneca, MedImmune, the contract research organization, or the study center employee or their close relatives.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04091373


Contacts
Layout table for location contacts
Contact: AstraZeneca Clinical Study Information Center 1-877-240-9479 information.center@astrazeneca.com

Locations
Layout table for location information
United States, Florida
Research Site Not yet recruiting
Daytona Beach, Florida, United States, 32117
Sponsors and Collaborators
MedImmune LLC

Layout table for additonal information
Responsible Party: MedImmune LLC
ClinicalTrials.gov Identifier: NCT04091373     History of Changes
Other Study ID Numbers: D5670C00025
First Posted: September 16, 2019    Key Record Dates
Last Update Posted: September 16, 2019
Last Verified: September 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Pediatric Postmarket Surveillance of a Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus, Type 2
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases